Home >> Research Area >>Natural Products>>Steroids>> Hyodeoxycholic acid

Hyodeoxycholic acid

CAS# 83-49-8

Hyodeoxycholic acid

Catalog No. BCN1287----Order now to get a substantial discount!

Product Name & Size Price Stock
Hyodeoxycholic acid: 5mg Please Inquire In Stock
Hyodeoxycholic acid: 10mg Please Inquire In Stock
Hyodeoxycholic acid: 20mg Please Inquire Please Inquire
Hyodeoxycholic acid: 50mg Please Inquire Please Inquire
Hyodeoxycholic acid: 100mg Please Inquire Please Inquire
Hyodeoxycholic acid: 200mg Please Inquire Please Inquire
Hyodeoxycholic acid: 500mg Please Inquire Please Inquire
Hyodeoxycholic acid: 1000mg Please Inquire Please Inquire

Quality Control of Hyodeoxycholic acid

Number of papers citing our products

Chemical structure

Hyodeoxycholic acid

3D structure

Chemical Properties of Hyodeoxycholic acid

Cas No. 83-49-8 SDF Download SDF
PubChem ID 23663448 Appearance White powder
Formula C24H40O4 M.Wt 392.56
Type of Compound Steroids Storage Desiccate at -20°C
Solubility Soluble to 78 mg/mL (198.69 mM) in DMSO
Chemical Name sodium;(4R)-4-[(3R,5R,6S,10R,13R,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
SMILES CC(CCC(=O)[O-])C1CCC2C1(CCC3C2CC(C4C3(CCC(C4)O)C)O)C.[Na+]
Standard InChIKey DUYSCILLIVEITB-IHUGHQDSSA-M
Standard InChI InChI=1S/C24H40O4.Na/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2;/h14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15-,16?,17-,18?,19?,20+,21+,23-,24-;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Hyodeoxycholic acid

The bile of Pig

Biological Activity of Hyodeoxycholic acid

DescriptionHyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells. Hyodeoxycholic acid has hypolipidemic effect through regulation of FXR activation, it is a candidate for antiatherosclerotic drug, by significantly increasing the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1,and Apoe,in a macrophage cell line.
TargetsFXR | LDL | TGR5 | NO | FAS
In vitro

Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.[Pubmed: 16750434]

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Sep 14;842(1):22-7.


METHODS AND RESULTS:
A simple, rapid, and specific analytical method for simultaneous determination of geniposide, baicalin, cholic acid and Hyodeoxycholic acid in 50 microL samples of rat serum was developed by high performance liquid chromatography-tandem mass spectrometry. The quantification of the target compounds was determined by multiple reaction monitoring (MRM) mode using electrospray ionization (ESI). The correlation coefficients of the calibration curves were better than 0.997. The intra- and inter-day accuracy, precision, and linear range had been investigated in detail.
CONCLUSIONS:
This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and Hyodeoxycholic acid in rats successfully.

In vivo

Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues.[Pubmed: 25189147]

Lipids. 2014 Oct;49(10):963-73.


METHODS AND RESULTS:
Mice were fed a control diet or a diet supplemented with Hyodeoxycholic acid, the most abundant bile acid contained in pig bile, for 4 weeks, after which their serum and livers were collected. The contents of total fatty acids of serum and liver cholesteryl esters, and of liver triglycerides, were reduced following the administration of the Hyodeoxycholic acid-supplemented diet, which was mainly due to the reductions in the contents of monounsaturated fatty acids. Free cholesterol contents in the serum and liver were not changed by Hyodeoxycholic acid administration. Hyodeoxycholic acid administration reduced the gene expression levels of sterol regulatory element binding protein 1c, acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA desaturase-1. Hyodeoxycholic acid administration markedly changes the ratio of FXR-antagonist/FXR-agonist bile acids in the enterohepatic tissues of the mice (1.13 and 7.60 in Hyodeoxycholic acid and control diet groups, respectively).
CONCLUSIONS:
Our findings demonstrate that Hyodeoxycholic acid administration exerts the hypolipidemic effect in mice, in which downregulations of de novo lipogenesis and desaturation of saturated fatty acids are suggested to play important roles. In addition, regulation of FXR activation through the selective modification of the enterohepatic bile acid pool may be involved in the hypolipidemic effect of Hyodeoxycholic acid administration.

Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.[Pubmed: 23752203]

FASEB J. 2013 Sep;27(9):3805-17.

We examined the effects of a natural secondary bile acid, Hyodeoxycholic acid (HDCA), on lipid metabolism and atherosclerosis in LDL receptor-null (LDLRKO) mice.
METHODS AND RESULTS:
Female LDLRKO mice were maintained on a Western diet for 8 wk and then divided into 2 groups that received chow, or chow + 1.25% HDCA, diets for 15 wk. We observed that mice fed the HDCA diet were leaner and exhibited a 37% (P<0.05) decrease in fasting plasma glucose level. HDCA supplementation significantly decreased atherosclerotic lesion size at the aortic root region, the entire aorta, and the innominate artery by 44% (P<0.0001), 48% (P<0.01), and 94% (P<0.01), respectively, as compared with the chow group. Plasma VLDL/IDL/LDL cholesterol levels were significantly decreased, by 61% (P<0.05), in the HDCA group as compared with the chow diet group. HDCA supplementation decreased intestinal cholesterol absorption by 76% (P<0.0001) as compared with the chow group. Furthermore, HDL isolated from the HDCA group exhibited significantly increased ability to mediate cholesterol efflux ex vivo as compared with HDL of the chow diet group. In addition, HDCA significantly increased the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1, and Apoe, in a macrophage cell line.
CONCLUSIONS:
Thus, HDCA is a candidate for antiatherosclerotic drug therapy.

Protocol of Hyodeoxycholic acid

Structure Identification
Molecules. 2013 Aug 30;18(9):10497-513.

Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives.[Pubmed: 23999724]

Bile acids have emerged as versatile signalling compounds of a complex network of nuclear and membrane receptors regulating various endocrine and paracrine functions. The elucidation of the interconnection between the biological pathways under the bile acid control and manifestations of hepatic and metabolic diseases have extended the scope of this class of steroids for in vivo investigations.
METHODS AND RESULTS:
In this framework, the design and synthesis of novel biliary derivatives able to modulate a specific receptor requires a deep understanding of both structure-activity and structure-property relationships of bile acids. In this paper, we report the preparation and the critical micellization concentration evaluation of a series of Hyodeoxycholic acid derivatives characterized by a diverse side chain length and by the presence of a methyl group at the alpha position with respect to the terminal carboxylic acid moiety.
CONCLUSIONS:
The data collected are instrumental to extend on a quantitative basis, the knowledge of the current structure-property relationships of bile acids and will be fruitful, in combination with models of receptor activity, to design and prioritize the synthesis of novel pharmacokinetically suitable ligands useful in the validation of bile acid-responsive receptors as therapeutic targets.

Hyodeoxycholic acid Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Hyodeoxycholic acid Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Hyodeoxycholic acid

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.5474 mL 12.7369 mL 25.4738 mL 50.9476 mL 63.6845 mL
5 mM 0.5095 mL 2.5474 mL 5.0948 mL 10.1895 mL 12.7369 mL
10 mM 0.2547 mL 1.2737 mL 2.5474 mL 5.0948 mL 6.3685 mL
50 mM 0.0509 mL 0.2547 mL 0.5095 mL 1.019 mL 1.2737 mL
100 mM 0.0255 mL 0.1274 mL 0.2547 mL 0.5095 mL 0.6368 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Hyodeoxycholic acid

Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.[Pubmed:16750434]

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Sep 14;842(1):22-7.

A simple, rapid, and specific analytical method for simultaneous determination of geniposide, baicalin, cholic acid and Hyodeoxycholic acid in 50 microL samples of rat serum was developed by high performance liquid chromatography-tandem mass spectrometry. The quantification of the target compounds was determined by multiple reaction monitoring (MRM) mode using electrospray ionization (ESI). The correlation coefficients of the calibration curves were better than 0.997. The intra- and inter-day accuracy, precision, and linear range had been investigated in detail. This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and Hyodeoxycholic acid in rats successfully.

Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.[Pubmed:23752203]

FASEB J. 2013 Sep;27(9):3805-17.

We examined the effects of a natural secondary bile acid, Hyodeoxycholic acid (HDCA), on lipid metabolism and atherosclerosis in LDL receptor-null (LDLRKO) mice. Female LDLRKO mice were maintained on a Western diet for 8 wk and then divided into 2 groups that received chow, or chow + 1.25% HDCA, diets for 15 wk. We observed that mice fed the HDCA diet were leaner and exhibited a 37% (P<0.05) decrease in fasting plasma glucose level. HDCA supplementation significantly decreased atherosclerotic lesion size at the aortic root region, the entire aorta, and the innominate artery by 44% (P<0.0001), 48% (P<0.01), and 94% (P<0.01), respectively, as compared with the chow group. Plasma VLDL/IDL/LDL cholesterol levels were significantly decreased, by 61% (P<0.05), in the HDCA group as compared with the chow diet group. HDCA supplementation decreased intestinal cholesterol absorption by 76% (P<0.0001) as compared with the chow group. Furthermore, HDL isolated from the HDCA group exhibited significantly increased ability to mediate cholesterol efflux ex vivo as compared with HDL of the chow diet group. In addition, HDCA significantly increased the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1, and Apoe, in a macrophage cell line. Thus, HDCA is a candidate for antiatherosclerotic drug therapy.

Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives.[Pubmed:23999724]

Molecules. 2013 Aug 30;18(9):10497-513.

Bile acids have emerged as versatile signalling compounds of a complex network of nuclear and membrane receptors regulating various endocrine and paracrine functions. The elucidation of the interconnection between the biological pathways under the bile acid control and manifestations of hepatic and metabolic diseases have extended the scope of this class of steroids for in vivo investigations. In this framework, the design and synthesis of novel biliary derivatives able to modulate a specific receptor requires a deep understanding of both structure-activity and structure-property relationships of bile acids. In this paper, we report the preparation and the critical micellization concentration evaluation of a series of Hyodeoxycholic acid derivatives characterized by a diverse side chain length and by the presence of a methyl group at the alpha position with respect to the terminal carboxylic acid moiety. The data collected are instrumental to extend on a quantitative basis, the knowledge of the current structure-property relationships of bile acids and will be fruitful, in combination with models of receptor activity, to design and prioritize the synthesis of novel pharmacokinetically suitable ligands useful in the validation of bile acid-responsive receptors as therapeutic targets.

Description

Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.

Keywords:

Hyodeoxycholic acid,83-49-8,Natural Products, buy Hyodeoxycholic acid , Hyodeoxycholic acid supplier , purchase Hyodeoxycholic acid , Hyodeoxycholic acid cost , Hyodeoxycholic acid manufacturer , order Hyodeoxycholic acid , high purity Hyodeoxycholic acid

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: